$10.45 -0.3 -2.6%
Last Trade - 08/03/21
| Market Cap | £508.8m |
| Enterprise Value | £497.7m |
| Revenue | £41.1m |
| Position in Universe | 3107th / 6647 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 31st Dec | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020E | 2021E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 15.3 | 22.0 | 21.7 | 21.2 | 31.6 | 46.3 | 59.2 | 79.2 | +24.8% | ||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Chromadex Corporation is an integrated nutraceutical company. The Company and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provides research and quality-control products and services to the natural products industry. The Company partners with universities and research institutions worldwide to discover, develop and create solutions to deliver the full potential of nicotinamide adenine dinucleotide (NAD) and its impact on human health. The Company’s operated segments are: Consumer Product, Ingredients, and Analytical Reference Standards and Service Segment. Its Consumer Product segment offers TRU NIAGEN to consumers worldwide. Its ingredients business segment develops and commercializes ingredients, including nicotinamide riboside (NR), for which its brand name is NIAGEN. It also develops pterostilbene, which is marketed and sold under its brand name, pTeroPure.
| Last Annual | December 31st, 2019 |
| Last Interim | September 30th, 2020 |
| Incorporated | June 19, 2008 |
| Public Since | November 17, 2008 |
| No. of Shareholders: | 51 |
| No. of Employees: | 110 |
| Sector | Healthcare |
| Industry | Biotechnology & Medical Research |
| Index | Nasdaq Composite , |
| Exchange | NASDAQ Capital Market |
| Shares in Issue | 65,633,881 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
As of 08/03/21, shares in Chromadex are trading at $10.45, giving the company a market capitalisation of £508.8m. This share price information is delayed by 15 minutes.
Shares in Chromadex are currently trading at $10.45 and the price has moved by 0.196k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Chromadex price has moved by 0.134k% over the past year.
Of the analysts with advisory recommendations for Chromadex, there are there are currently 2 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Chromadex is Buy. You can view the full broker recommendation list by unlocking its StockReport.
Chromadex is scheduled to issue upcoming financial results on the following dates:
Chromadex does not currently pay a dividend.
Chromadex does not currently pay a dividend.
Chromadex does not currently pay a dividend.
To buy shares in Chromadex you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Chromadex are currently trading at $10.45, giving the company a market capitalisation of £508.8m.
Here are the trading details for Chromadex:
Based on an overall assessment of its quality, value and momentum, Chromadex is currently classified as a High Flyer. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Chromadex are currently priced at $10.45. At that level they are trading at 26.37% premium to the analyst consensus target price of 0.00.
Analysts covering Chromadex currently have a consensus Earnings Per Share (EPS) forecast of -0.318 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Chromadex. Over the past six months, the relative strength of its shares against the market has been 0.110k%. At the current price of $10.45, shares in Chromadex are trading at 0.105k% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
We were not able to find PE ratio data for Chromadex.
Chromadex's management team is headed by:
Here are the top five shareholders of Chromadex based on the size of their shareholding:
